Analysts Offer Predictions for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB) – Investment analysts at HSBC issued their Q1 2026 earnings per share (EPS) estimates for Biogen in a report released on Friday, April 17th. HSBC analyst M. Herholdt anticipates that the biotechnology company will post earnings per share of $2.87 for the quarter. HSBC currently has a “Reduce” rating and a $150.00 target price on the stock. The consensus estimate for Biogen’s current full-year earnings is $15.70 per share. HSBC also issued estimates for Biogen’s Q2 2026 earnings at $4.38 EPS, Q3 2026 earnings at $4.28 EPS, Q4 2026 earnings at $4.53 EPS and FY2030 earnings at $15.53 EPS.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the company earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS.

BIIB has been the subject of several other research reports. Barclays initiated coverage on Biogen in a research note on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price target for the company. Royal Bank Of Canada cut their price objective on Biogen from $233.00 to $213.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 7th. Truist Financial dropped their price target on Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a research report on Monday, April 13th. The Goldman Sachs Group reissued a “buy” rating on shares of Biogen in a research report on Monday, February 9th. Finally, Oppenheimer boosted their price target on Biogen from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. Thirteen investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $208.23.

Biogen Trading Up 1.4%

Shares of BIIB stock opened at $185.95 on Tuesday. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The business has a 50-day moving average price of $185.55 and a two-hundred day moving average price of $174.62. Biogen has a 12-month low of $115.25 and a 12-month high of $202.41. The firm has a market cap of $27.29 billion, a P/E ratio of 21.11, a price-to-earnings-growth ratio of 2.46 and a beta of 0.16.

Institutional Investors Weigh In On Biogen

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Poehling Capital Management INC. purchased a new stake in shares of Biogen in the 1st quarter worth $210,000. Aaron Wealth Advisors LLC bought a new position in Biogen in the 1st quarter worth $217,000. Louisiana State Employees Retirement System bought a new position in Biogen in the 1st quarter worth $1,375,000. Contravisory Investment Management Inc. bought a new position in shares of Biogen during the 1st quarter valued at about $8,191,000. Finally, Ritholtz Wealth Management boosted its holdings in shares of Biogen by 23.1% during the 1st quarter. Ritholtz Wealth Management now owns 34,943 shares of the biotechnology company’s stock valued at $6,406,000 after purchasing an additional 6,568 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen agreed to acquire exclusive Greater China rights to felzartamab (up to $850M), giving Biogen consolidated worldwide development and commercialization control of a CD38‑directed antibody currently in global Phase 3 trials — a meaningful commercial and strategic upside if late‑stage data and approvals succeed. Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
• Positive Sentiment: Wells Fargo upgraded BIIB to Overweight and boosted its price target to $250, a high‑profile bullish call that likely supported buying interest and helped lift the shares. Wells Fargo Upgrades Biogen to Overweight
• Neutral Sentiment: Coverage and media rundowns noted BIIB among names with large moves after the felzartamab news; these summaries amplify awareness but don’t add new fundamentals. Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen
• Neutral Sentiment: Recent earnings transcripts and previews (Q2 and Q3 filings/transcripts) reiterate management’s guidance and pipeline priorities but contained no surprise revisions that would immediately change the investment thesis. Biogen (BIIB) Q2 2025 Earnings Transcript Biogen (BIIB) Q3 2025 Earnings Transcript
• Negative Sentiment: HSBC reiterated a “Reduce” rating and set a $150 target while publishing mid‑cycle EPS estimates — a notable sell‑side headwind that provides a lower valuation anchor for skeptical investors. MarketBeat BIIB page (HSBC note referenced)
• Negative Sentiment: Opinion pieces arguing reasons to avoid BIIB highlight valuation and execution risks despite recent gains — these stories can temper momentum and attract short‑term profit‑taking. 3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.